TPEXTREME RANDOMIZED TRIAL PUBLISHED IN LANCET

April 2021

Taxane-based TPEx regimen appears to be a new option in first line recurrent/metastatic HNSCC, with a shorter time on therapy and lower toxicity than the reference EXTREME regimen. This can provide an alternative to SOC with EXTREME regimen, especially for those who may not be good candidates for up-front pembrolizumab. https://pubmed.ncbi.nlm.nih.gov/33684370/

Recent Posts

See All

ARTICLE ON THE FORMATION OF THE HNCIG PUBLISHED IN ORAL ONCOLOGY

July 10, 2017 An article describing the formation of the HNCIG as well as its objectives, structure, and activities was published in Oral...

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA

HNCIG CONSENSUS GUIDELINES FOR POSTOPERATIVE RADIATION IN COMPLEX CUTANEOUS SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK July 15, 2020...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY...

ASTRO-ESTRO CONSENSUS STATEMENT ON RISK-ADAPTED HEAD AND NECK CANCER RADIATION THERAPY DURING THE COVID-19 PANDEMIC PUBLISHED IN RED...

TPEXTREME RANDOMIZED TRIAL PUBLISHED IN LANCET

Recent Posts

Comentarios